What patients most want to know about durability

For most patients considering ChondroFiller injection, the practical question is a simple one: will the benefit last, and will I need to come back for it again?

The direct answer is that the clinical benefit is durable at one year — the point at which the collagen scaffold has degraded and the body's own cartilage matrix has matured through acellular matrix-induced chondrogenesis. Beyond 12 months, longer-horizon evidence exists in the published literature and it supports a sustained regenerative effect. That evidence comes from surgically implanted studies rather than the outpatient injection pathway, so it functions here as supporting context rather than a direct read-across — the injection-specific follow-up picture is solid at 12 months and continues to develop in the literature beyond that point.

On the question of repeat treatment: a structured maintenance programme is part of the clinical protocol, including a top-up injection on a bi-annual basis alongside annual MRI monitoring. This is not a signal that the initial effect fades quickly; it reflects a proactive joint-preservation approach rather than a rescue response to failure.

How durable any individual's outcome proves to be is also materially shaped by baseline joint health — particularly the degree of pre-existing osteoarthritis — and this is discussed in the context of patient selection further in the article.

What 12-month evidence shows for the knee

The two published knee cohort studies provide the most directly applicable evidence for patients considering ChondroFiller injection. A 2016 randomised controlled trial (n=13) and a 2024 cohort from University Hospital Pleven, Bulgaria (n=17, mean age 31) both documented significant IKDC improvements at three, six, and twelve months — with gains of approximately 30 points over baseline, a threshold that corresponds to a meaningful shift in day-to-day joint function.

Both studies found that patient-reported scores stabilised between six and twelve months: the difference between the six-month and twelve-month assessments was not statistically significant in either cohort. Patients typically notice the benefit settling by around six months.

MRI tells a different story at the tissue level. In the 2016 study, MOCART scores — which quantify cartilage fill quality on imaging — showed complete defect filling as early as week four, then continued to improve progressively through to week 52. So while a patient's symptoms settle around the six-month mark, the cartilage itself carries on maturing inside the joint over the following year. The scaffold's biological work outlasts the point at which the patient notices the improvement.

Twelve months is the established published horizon for the injection modality in the knee. That should be read as the best-documented window, not a ceiling — ongoing remodelling beyond that point is biologically consistent with what the tissue data show, and longer-horizon evidence is addressed in the following section.

Longer-horizon evidence from surgical implantation studies

Beyond the 12-month mark, the most informative published evidence on ChondroFiller scaffold durability comes from a 2021 prospective hip cohort — and it is important to read that evidence in context.

In that study (n=26 patients, follow-up at 12 to 60 months), 17 of 21 evaluable participants — 81% — reported good or excellent outcomes at consecutive three-, four-, and five-year assessments. Those figures represent the strongest published signal that the regenerative output of the ChondroFiller scaffold can persist well into the medium term. Baseline joint health proved central: patients with pre-existing osteoarthritis at Tönnis grade 2 or 3 had poor outcomes, whilst those with healthier joints at the outset fared substantially better. That finding reinforces the importance of patient selection in shaping how durable any individual's result proves to be.

The critical caveat is the delivery route. This cohort used arthroscopic surgical implantation — a theatre-based procedure requiring a dry joint field and direct defect preparation — rather than the outpatient, ultrasound-guided injection pathway currently in use. The two paradigms differ in technique, joint environment, and defect-filling geometry, so the surgical figures cannot be taken as a direct read-across to the injection route.

They do, however, speak to the scaffold's underlying biological potential: the collagen matrix and the chondrogenesis it induces are the same whether delivered surgically or by injection. No published study currently tracks injection-route patients to the three-to-five-year window.

Why tissue type is the key to lasting results

Durability is not simply a question of whether a defect fills — it depends on what fills it. The body can respond to cartilage injury in two quite different ways: it may lay down hyaline-like tissue, which closely resembles native articular cartilage in its structure and load-bearing properties, or it may produce fibrocartilage, a tougher but mechanically inferior substitute that tends to degrade more quickly under the repetitive stress of a working joint.

ChondroFiller injection works through acellular matrix-induced chondrogenesis — the collagen scaffold recruits the patient's own progenitor cells, which migrate in and differentiate into chondrocytes capable of depositing Type II collagen-rich, hyaline-like matrix. Microfracture, by comparison, stimulates a wound-healing response that predominantly produces Type I collagen fibrocartilage. That biological difference has a practical downstream consequence: in comparative data drawn from the manufacturer's Clinical Evaluation Report (April 2025), ChondroFiller reoperation rates sit at 3–8%, against rates of up to 41% following microfracture.

Histological evidence published in 2025 from a wrist study (n=8 with follow-up arthroscopy) provides direct tissue-level confirmation. ChondroFiller-treated defects showed markedly better cartilage grades — median Outerbridge 1.5 versus 3 in untreated controls, and ICRS grade 1 versus grade 3 (p<0.01). One finding from that study carries a direct clinical implication: defects that were overfilled developed fibrous tissue formation, whereas flush-level applications were free of it. The quality of the regenerative output is therefore not solely a product property — it depends on precise, controlled placement. That is one reason why image-guided technique and the experience of the clinician performing the injection materially affect the durability of the result.

The first weeks after injection: why the scaffold needs time

Setting the right expectations for the first weeks after injection matters as much as understanding the long-term evidence.

When ChondroFiller is first placed, the collagen scaffold gels rapidly in situ and begins recruiting the patient's own progenitor cells — but mechanical integration takes time. A 2024 in vitro porcine loading study found that in its initial, unintegrated state the scaffold does not protect the opposing articular surface under cyclic loading. The authors concluded that full weight-bearing should be delayed until stable integration has been achieved.

This is not a signal that something has gone wrong. It is a predictable feature of scaffold biology: cell migration, chondrocyte differentiation, and matrix deposition occur progressively over weeks. The scaffold is doing meaningful biological work from the outset — the early load-protection window simply reflects the interval between biological activation and mechanical maturity.

That interval is the clinical rationale for post-injection rehabilitation guidance. Protecting the joint during the integration phase — through activity modification, graded return to loading, and avoiding high-impact stress — gives the scaffold the conditions it needs to consolidate properly. The clinical team's rehabilitation plan is designed around this biology specifically; the load-management restrictions lift as integration progresses and the developing repair tissue becomes capable of bearing the demands placed on it.

Repeat injection intervals and the maintenance programme

Maintenance planning begins where the initial benefit stabilises. The documented repeat-injection cadence — drawn from the platform's Longitudinal Lifetime Program clinical protocol — is a bi-annual ChondroFiller top-up, meaning a further injection approximately every two years, combined with annual MRI monitoring to track cartilage integrity between treatments. It is worth being transparent about the provenance of that figure: the two-year interval reflects institutional clinical experience and programme design, not a published randomised controlled trial on optimal re-treatment timing for the injection route. Controlled trial data at that level does not yet exist.

The annual MRI serves a specific function within the programme: changes in cartilage status can be detected on imaging before symptoms deteriorate, allowing the clinical team to act on early signals rather than wait for the patient to notice a change. That proactive monitoring loop is what makes the approach a joint-preservation programme rather than a series of reactive one-off treatments.

That framing holds most firmly for patients whose baseline joint health is good — a pattern that runs consistently through the published evidence. The maintenance model is a tool for preserving a joint that still has meaningful function; it complements, but does not replace, attention to the biomechanical and lifestyle factors that determine how quickly cartilage degrades in the first place.

1. [1] Controlled, randomized multicenter study to compare compatibility and safety of ChondroFiller liquid with microfracturing of patients with focal cartilage defects of the knee joint. (2016). https://doi.org/10.5348/VNP05-2016-1-OA-1 https://doi.org/10.5348/VNP05-2016-1-OA-1
2. [2] Arthroscopic utilization of ChondroFiller gel for the treatment of hip articular cartilage defects: a cohort study with 12- to 60-month follow-up. (2021). https://doi.org/10.1093/jhps/hnab002 https://doi.org/10.1093/jhps/hnab002
3. [3] Cartilage reconstruction using Chondrofiller in intra-articular distal radius fractures. (2025). https://doi.org/10.1186/s42836-025-00333-y https://doi.org/10.1186/s42836-025-00333-y
4. [4] Implantation of ChondroFiller Liquid® as a scaffold material for the treatment of chondral lesions of the knee joint. (2024). https://doi.org/10.5272/jimab.2024304.5936 https://doi.org/10.5272/jimab.2024304.5936
5. [5] Influence of cartilage defects and a collagen gel on integrity of corresponding intact cartilage: a biomechanical in-vitro study. (2024). https://doi.org/10.1007/s00402-024-05530-z https://doi.org/10.1007/s00402-024-05530-z